Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Åke Lernmark

Principal investigator

Default user image.

Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents

Author

  • Johnny Ludvigsson
  • Annelie Carlsson
  • Ahmed Deli
  • Gun Forsander
  • Sten Ivarsson
  • Ingrid Kockum
  • Bengt Lindblad
  • Claude Marcus
  • Ake Lernmark
  • Ulf Samuelsson

Summary, in English

Aims/hypothesis: We studied the decline of C-peptide during the first year after diagnosis of Type 1 diabetes (T1D), and its relation to various factors. Methods: 3824/4017 newly diagnosed patients (95%) were classified as T1D in a national study. In a non-selected subgroup of 1669 T1D patients we determined non-fasting C-peptide both at diagnosis and after 1 year, and analyzed decline in relation to clinical symptoms and signs, initial C-peptide and occurrence of auto-antibodies. Results: Younger children lost more C-peptide (p < 0.001) and the higher the C-peptide at diagnosis the larger the decline during the first year (p < 0.0000). Patients with higher BMI had higher C-peptide at diagnosis but lost more (p < 0.01), and those with lower HbA1c, without symptoms and signs at diagnosis, and with higher BMI, had higher C-peptide at diagnosis, but lost more during the first year (p < 0.001). Finally, patients diagnosed during autumn had higher C-peptide at diagnosis, but lost more during the coming year (p < 0.001). Occurrence of auto-antibodies did not correlate with C-peptide decline, except possibly for a more rapid loss in IAA-positive patients. Conclusions/interpretation: Even in a restricted geographical area and narrow age range (< 18 years), the natural course of Type 1 diabetes is heterogeneous. This should be considered in clinical trials. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

Department/s

  • Paediatrics (Lund)
  • Paediatric Endocrinology
  • Vascular Diseases - Clinical Research
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Diabetes and Celiac Unit

Publishing year

2013

Language

English

Pages

203-209

Publication/Series

Diabetes Research and Clinical Practice

Volume

100

Issue

2

Document type

Journal article

Publisher

Elsevier

Topic

  • Endocrinology and Diabetes

Keywords

  • C-peptide
  • Natural course
  • Type 1 diabetes
  • Children
  • BMI
  • Intervention
  • trials

Status

Published

Research group

  • Paediatric Endocrinology
  • Vascular Diseases - Clinical Research
  • Diabetes and Celiac Unit

ISBN/ISSN/Other

  • ISSN: 1872-8227